ERBB2 and breast carcinoma: Based on the histopathological results, we categorized patients with breast cancer into the following groups: (i) triple-negative patients (ER-, PR-, Her2-; TNBC), (ii) (ER+, PR+, HER2+), (iii) (ER+, PR+, HER2-), (iv) (ER-, PR-, HER2+), (v) other subtypes.